Evidence map›Paper›PMID 32888134›Full record

ArticleFamilial cancer2021

Genetic testing and surveillance in infantile myofibromatosis: a report from the SIOPE Host Genome Working Group.

Simone Hettmer, Guillaume Dachy, Guido Seitz, Abbas Agaimy, Catriona Duncan, Marjolijn Jongmans, Steffen Hirsch, Iris Kventsel, Uwe Kordes, Ronald R de Krijger and 12 more

Open access · hybridAbstract read
In one paragraph

Article in Familial cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Novel COL4A1-VEGFD gene fusion in myofibroma.Journal of cellular and molecular medicine · 2021
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 18 institutions in 8 countries.

Simone HettmerDivision of Pediatric Hematology and Oncology, Department of Pediatric and Adolescent Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany. simone.hettmer@uniklinik-freiburg.de.ORCID 0000-0003-1709-4448
Guillaume DachyDe Duve Institute, University of Louvain, Brussels, Belgium.
Guido SeitzDepartment of Pediatric Surgery, University Hospital Gießen-Marburg, Marburg, Germany.
Abbas AgaimyInstitute of Pathology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital, Erlangen, Germany.
Catriona DuncanDivision of Pediatric Oncology, Great Ormond Street Hospital, London, Great Britain, UK.
Marjolijn JongmansPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Steffen HirschInstitute of Human Genetics, Heidelberg University Hospital, Heidelberg, Germany.
Iris KventselDivision of Pediatric Oncology, Sheba Medical Center, Ramat Gan, Israel.
Uwe KordesDepartment of Pediatric Hematology/Oncology, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
Ronald R de KrijgerPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Markus MetzlerDepartment of Pediatric and Adolescent Medicine, Children's Hospital, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Orli MichaeliDivision of Hematology/Oncology, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
Karolina NemesSwabian Children's Cancer Center, Children's Hospital Augsburg, Augsburg, Germany.
Anna PoluhaDepartment of Clinical Genetics, Uppsala University Hospital, Uppsala, Sweden.
Tim RippergerDepartment of Human Genetics, Hannover Medical School, Hannover, Germany.
Alexandra RussoSection of Pediatric Oncology, Children's Hospital, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Stephanie SmetsersPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Monika Sparber-SauerOlgahospital, Klinikum Stuttgart, Stuttgart, Germany.
Eveline StutzPediatric Oncology, University Children's Hospital Zürich, Zürich, Switzerland.
Franck BourdeautSIREDO Pediatric Cancer Center, Institute Curie, Paris, France.
Christian P KratzDivision of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
Jean-Baptiste DemoulinDe Duve Institute, University of Louvain, Brussels, Belgium. jean-baptiste.demoulin@uclouvain.be.
de Duve Institute · BEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEMedizinische Hochschule Hannover · DEUniversity Medical Center Utrecht · NLGreat Ormond Street Hospital · GBHeidelberg University · DEInstitut Curie · FRJohannes Gutenberg University Mainz · DEOlgahospital · DEPrincess Máxima Center · NLSchneider Children's Medical Center · ILSheba Medical Center · ILUniversität Hamburg · DEUniversitätsklinikum Gießen und Marburg · DEUniversity Children's Hospital Zurich · CHUniversity Hospital Augsburg · DEUniversity of Freiburg · DEUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infantile myofibromatosis (IM), which is typically diagnosed in young children, comprises a wide clinical spectrum ranging from inconspicuous solitary soft tissue nodules to multiple disseminated tumors resulting in life-threatening complications. Familial IM follows an autosomal dominant mode of inheritance and is linked to PDGFRB germline variants. Somatic PDGFRB variants were also detected in solitary and multifocal IM lesions. PDGFRB variants associated with IM constitutively activate PDGFRB kinase activity in the absence of its ligand. Germline variants have lower activating capabilities than somatic variants and, thus, require a second cis-acting hit for full receptor activation. Typically, these mutant receptors remain sensitive to tyrosine kinase inhibitors such as imatinib. The SIOPE Host Genome Working Group, consisting of pediatric oncologists, clinical geneticists and scientists, met in January 2020 to discuss recommendations for genetic testing and surveillance for patients who are diagnosed with IM or have a family history of IM/PDGFRB germline variants. This report provides a brief review of the clinical manifestations and genetics of IM and summarizes our interdisciplinary recommendations.

Indexed as

MyofibromatosisChildChild, PreschoolGenetic TestingHumansImatinib MesylateReceptor, Platelet-Derived Growth Factor betaImatinib MesylateReceptor, Platelet-Derived Growth Factor betaGenetic counselingInfantile myofibromatosisPDGFRB variantsSurveillance

Identifiers

PMID32888134
PMCPMC8484085
OpenAlexW3083157445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.